Jeito, INKEF, Forbion lead EUR 80m Series B for Precirix

Existing investors Gimv, HealthCap, Novo Holdings, Pontifax Venture Capital, V-Bio Ventures, and BioMed Partners also invested in the round. 

Precirix is a spin-out from the Vrije Universiteit Brussel (VUB). It last raised a EUR 37m Series A in 2018

Precirix’s platform brings together several radiolabelled single-domain antibodies (sdAbs) for multiple cancer targets. 

The funds will be used to expand Precirix’s pipeline and advance its main product candidate, CAM-H2, which is currently in a Phase I/II study for the treatment of HER2-positive metastatic breast and gastric cancer.

The new investors are also helping Precirix to develop a roadmap to treat brain metastases. 

"First, we invested because it is very strong science from a good Belgian university," Sabine Dandiguian from Jeito Capital told Unquote. "Secondly, it's a hot area of radiopharmaceuticals. A unique product that can help patients who are almost helpless." 

Dandiguian, alongside Simone Botti from INKEF Capital and Jasper Bos at Forbion Growth will join Precirix’s board. 

Forbion is investing through its Forbion Growth fund, which closed in April last year at EUR 360m. Jeito is investing through its first fund, Jeito Capital I, which closed in September last year at EUR 534m. 

INKEF closed its first and only fund, which has a 15-year life span, in 2016 at EUR 500M. 

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Healthcare
• Expansion
• Benelux
• healthcare